{
  "id": 11296486,
  "title": "Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?",
  "url": "https://urgent.news/2026/10/01/johnson-johnson-vs-eli-lilly-which-pharma-stock-can-make-your",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T21:53:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/10/01/johnson-and-johnson-vs-eli-lilly-which-pharma-stock-can-make-your-portfolio-healthier-in-2026/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "In 2026, investors eyeing the healthcare sector face a choice between Johnson & Johnson and Eli Lilly. Both companies offer distinct advantages, catering to investors with different risk appetites and growth expectations. Johnson & Johnson, with its diversified portfolio, stands as a stable anchor, while Eli Lilly promises rapid growth through its focus on innovative treatments.",
  "summary": "JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?",
        "url": "https://urgent.news/2026/10/01/johnson-johnson-vs-eli-lilly-which-pharma-stock-can-make-your-11297353",
        "published": "2026-10-01T22:13:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}